Semaglutide
Symbol Sg · MW 4114 Da
GLP-1 receptor agonist used for glycemic control and weight management.
- Discovered
- 2004
- Half-life
- 7 days
- Approval
- FDA-approved (Ozempic, Wegovy, Rybelsus)
Reported effects
- Appetite regulation
- Glucose control
- Significant weight loss
Overview
Semaglutide is a GLP-1 receptor agonist peptide widely known for its role in weight loss, appetite control, and type 2 diabetes management. It works by activating GLP-1 receptors, which help regulate hunger, insulin secretion, blood sugar levels, and stomach emptying. Semaglutide supports weight management by reducing appetite, increasing fullness, and helping lower overall calorie intake. Because of its long half-life, injectable Semaglutide is commonly dosed once weekly, while oral versions are also available for specific medical uses. As one of the most recognized weight loss peptides, Semaglutide has become a major part of modern obesity and metabolic health treatment.
How it's taken
- Typical Administration
- Injectable / Oral
- Typical Dosage
- Injectable: 0.25–2.4 mg; oral tablet: 1.5–25 mg depending on indication and titration schedule
- Typical Frequency
- Injectable once weekly; oral once daily
Research sources
Source links included from peer-reviewed literature and trusted medical journal records for this peptide.
Interested in Semaglutide?
Enter your email and we'll send you a curated list of vendors we trust for sourcing this peptide.
No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions.